Skip to main content

Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.

Publication ,  Journal Article
Ascheim, DD; Gelijns, AC; Goldstein, D; Moye, LA; Smedira, N; Lee, S; Klodell, CT; Szady, A; Parides, MK; Jeffries, NO; Skerrett, D; Rame, JE ...
Published in: Circulation
June 3, 2014

BACKGROUND: Allogeneic mesenchymal precursor cells (MPCs) injected during left ventricular assist device (LVAD) implantation may contribute to myocardial recovery. This trial explores the safety and efficacy of this strategy. METHODS AND RESULTS: In this multicenter, double-blind, sham-procedure controlled trial, 30 patients were randomized (2:1) to intramyocardial injection of 25 million MPCs or medium during LVAD implantation. The primary safety end point was incidence of infectious myocarditis, myocardial rupture, neoplasm, hypersensitivity reaction, and immune sensitization (90 days after randomization). Key efficacy end points were functional status and ventricular function while temporarily weaned from LVAD support (90 days after randomization). Patients were followed up until transplant or 12 months after randomization, whichever came first. Mean age was 57.4 (±13.6) years, mean left ventricular ejection fraction was 18.1%, and 66.7% were destination therapy LVADs. No safety events were observed. Successful temporary LVAD weaning was achieved in 50% of MPC and 20% of control patients at 90 days (P=0.24); the posterior probability that MPCs increased the likelihood of successful weaning was 93%. At 90 days, 3 deaths (30%) occurred in control patients, and none occurred in MPC patients. Mean left ventricular ejection fraction after successful wean was 24.0% (MPC=10) and 22.5% (control=2; P=0.56). At 12 months, 30% of MPC patients and 40% of control patients were successfully temporarily weaned from LVAD support (P=0.69), and 6 deaths (30%) occurred in MPC patients. Donor-specific HLA sensitization developed in 2 MPC and 3 control patients and resolved by 12 months. CONCLUSIONS: In this preliminary trial, administration of MPCs appeared to be safe, and there was a potential signal of efficacy. Future studies will evaluate the potential for higher or additional doses to enhance the ability to wean LVAD recipients off support. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01442129.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

June 3, 2014

Volume

129

Issue

22

Start / End Page

2287 / 2296

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Myocarditis
  • Middle Aged
  • Mesenchymal Stem Cells
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Incidence
  • Humans
  • Heart-Assist Devices
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ascheim, D. D., Gelijns, A. C., Goldstein, D., Moye, L. A., Smedira, N., Lee, S., … Woo, Y. J. (2014). Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation, 129(22), 2287–2296. https://doi.org/10.1161/CIRCULATIONAHA.113.007412
Ascheim, Deborah D., Annetine C. Gelijns, Daniel Goldstein, Lemuel A. Moye, Nicholas Smedira, Sangjin Lee, Charles T. Klodell, et al. “Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.Circulation 129, no. 22 (June 3, 2014): 2287–96. https://doi.org/10.1161/CIRCULATIONAHA.113.007412.
Ascheim DD, Gelijns AC, Goldstein D, Moye LA, Smedira N, Lee S, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014 Jun 3;129(22):2287–96.
Ascheim, Deborah D., et al. “Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices.Circulation, vol. 129, no. 22, June 2014, pp. 2287–96. Pubmed, doi:10.1161/CIRCULATIONAHA.113.007412.
Ascheim DD, Gelijns AC, Goldstein D, Moye LA, Smedira N, Lee S, Klodell CT, Szady A, Parides MK, Jeffries NO, Skerrett D, Taylor DA, Rame JE, Milano C, Rogers JG, Lynch J, Dewey T, Eichhorn E, Sun B, Feldman D, Simari R, O’Gara PT, Taddei-Peters WC, Miller MA, Naka Y, Bagiella E, Rose EA, Woo YJ. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014 Jun 3;129(22):2287–2296.

Published In

Circulation

DOI

EISSN

1524-4539

Publication Date

June 3, 2014

Volume

129

Issue

22

Start / End Page

2287 / 2296

Location

United States

Related Subject Headings

  • Ventricular Dysfunction, Left
  • Treatment Outcome
  • Myocarditis
  • Middle Aged
  • Mesenchymal Stem Cells
  • Mesenchymal Stem Cell Transplantation
  • Male
  • Incidence
  • Humans
  • Heart-Assist Devices